Clayton Medical Research Foundation

The Tumor Targeting Toxins grant to the University of California, San Diego, funds research directed to the discovery and development of compounds for cancer therapy, compounds synthesized with proteins joined by a sortase reaction, and compounds with cancer stem cell and hormone targeting ligands coupled with toxins for delivery to ovarian tumors and other epithelial tumors. Patent applications have been filed for these technologies by Research Development Foundation ("RDF"), a tax-exempt supporting organization of the Foundation (see Schedule R, Part III), and collaborations have been and are being established with other scientists and with commercial entities and consultants for manufacturing and development of drugs for human cancer indications.

A medical research grant to The University of California, Irvine for research collaboration with The University of Texas Health Science Center San Antonio involving the design and development of new technology and devices based on the use of light for diagnosis, guidance and surgery in cardiological and other medical applications, including possible use in treatment of coronary total occlusion and coronary artery diseases and technologies to allow stenting intravascular coronary arteries that are narrowed or blocked due to calcification. Research to date on this project has resulted in several issued patents and a number of pending patent applications have been filed. Licensing discussions are currently in progress with a commercial entity that will take on the clinical development of one of these technologies.

STF-1 and Glucose Control grant to The Salk Institute for Biological Studies focuses on characterization of cellular proteins that modulate fatty acid metabolism in muscle and fat; characterization of a signaling module that promotes beta cell survival; and the role of PDX and other known and new molecular switches in promoting beta islet cell proliferation and insulin secretion in the pancreas and liver.